Targeting the tumor stroma for cancer therapy

M Xu, T Zhang, R Xia, Y Wei, X Wei - Molecular Cancer, 2022 - Springer
Tumors are comprised of both cancer cells and surrounding stromal components. As an
essential part of the tumor microenvironment, the tumor stroma is highly dynamic …

TGFβ biology in cancer progression and immunotherapy

R Derynck, SJ Turley, RJ Akhurst - Nature Reviews Clinical Oncology, 2021 - nature.com
TGFβ signalling has key roles in cancer progression: most carcinoma cells have inactivated
their epithelial antiproliferative response and benefit from increased TGFβ expression and …

Harnessing natural killer cells for cancer immunotherapy: dispatching the first responders

NA Maskalenko, D Zhigarev… - Nature reviews Drug …, 2022 - nature.com
Natural killer (NK) cells have crucial roles in the innate immunosurveillance of cancer and
viral infections. They are 'first responders' that can spontaneously recognize abnormal cells …

Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma

Y Qian, Y Gong, Z Fan, G Luo, Q Huang… - Journal of hematology & …, 2020 - Springer
Pancreatic ductal adenocarcinoma (PDAC) is a malignancy characterized by a poor
prognosis and high mortality rate. Genetic mutations and altered molecular pathways serve …

Steps in metastasis: an updated review

J Majidpoor, K Mortezaee - Medical Oncology, 2021 - Springer
Metastasis is the most complex and deadly event. Tumor-stromal interface is a place where
invasion of tumor cells in the form of single-cell or collective migration occurs, with the latter …

[HTML][HTML] Clinical development of therapies targeting TGFβ: current knowledge and future perspectives

D Ciardiello, E Elez, J Tabernero, J Seoane - Annals of Oncology, 2020 - Elsevier
Transforming growth factor beta (TGFβ) is a pleiotropic cytokine that plays a key role in both
physiologic and pathologic conditions, including cancer. Importantly, TGFβ can exhibit both …

[HTML][HTML] Safety and activity of the TGFβ receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer

D Melisi, DY Oh, A Hollebecque, E Calvo… - … for immunotherapy of …, 2021 - ncbi.nlm.nih.gov
Background We assessed the safety, efficacy, and pharmacokinetics of the transforming
growth factor beta (TGFβ) receptor inhibitor galunisertib co-administered with the anti …

Context-dependent TGFβ family signalling in cell fate regulation

L Richardson, SG Wilcockson, L Guglielmi… - … Reviews Molecular Cell …, 2023 - nature.com
The transforming growth factor-β (TGFβ) family are a large group of evolutionarily conserved
cytokines whose signalling modulates cell fate decision-making across varying cellular …

Cancer-associated fibroblasts: understanding their heterogeneity

K Louault, RR Li, YA DeClerck - Cancers, 2020 - mdpi.com
Simple Summary Cancer-associated fibroblasts (CAFs) play an important contributory role in
the microenvironment of tumors. They originate from different cells, have multiple pro-and …

Epithelial–mesenchymal transition: The history, regulatory mechanism, and cancer therapeutic opportunities

Z Huang, Z Zhang, C Zhou, L Liu, C Huang - MedComm, 2022 - Wiley Online Library
Epithelial–mesenchymal transition (EMT) is a program wherein epithelial cells lose their
junctions and polarity while acquiring mesenchymal properties and invasive ability …